U.S. Veterinary Oncology Market Challenges, Import Export Consumption, Demand and Forecast 2030

U.S. Veterinary Oncology Market Summary

The U.S. veterinary oncology market size was estimated at USD 722.86 million in 2024 and is projected to expand at a CAGR of 12.58% from 2025 to 2030. The market growth is primarily driven by advancements in cancer treatment technologies such as stereotactic radiation therapy, coupled with increasing pet ownership and rising expenditure on advanced healthcare services. Additionally, the growing prevalence of cancer in pets has significantly contributed to the need for veterinary oncology services. For instance, according to an article published by Cancer Letter Inc. in May 2024, nearly 6 million dogs are diagnosed with cancer every year in the U.S., making cancer one of the leading causes of death, particularly among older dogs.

The industry is also witnessing accelerated growth due to a surge in clinical trials and regulatory approvals for advanced cancer therapies, reflecting a broader transition toward precision and translational medicine in veterinary healthcare. A notable example includes the approval of ELIAS Cancer Immunotherapy (ECI) by ELIAS Animal Health in March 2025, marking the first adoptive cell therapy approved by the USDA for canine osteosarcoma. ECI leverages a dog’s immune system by activating killer T cells to specifically target cancer cells, representing a significant milestone in canine oncology. Currently, this therapy is available at 100 authorized treatment centers across the U.S., providing a groundbreaking treatment option, particularly for large breed dogs at higher risk of developing bone cancer.

Key Market Trends & Insights

• Based on animal type, the market is segmented into canine, feline, and equine. The canine segment held the largest market share of 86.28% in 2024 and is also expected to be the fastest-growing segment with a projected CAGR of 13.22% over the forecast period. Dogs are more prone to various cancers compared to other pets, which increases the demand for oncology services, diagnostic solutions, and innovative treatment methods within this segment.
• Based on therapy, surgery accounted for the largest share of 36.02% in 2024. This dominance can be attributed to the effectiveness of surgical procedures in removing tumors and managing localized cancers. The adoption of advanced surgical techniques and technologies, offering improved accuracy and higher success rates, has fueled the preference for surgical interventions among veterinary oncologists.
• In terms of cancer type, the skin cancers segment led the market with a share of 39.0% in 2024. According to a report published by Morris Animal Foundation in June 2024, skin cancer was identified as the most common type of cancer in companion animals, particularly in dogs and cats, thereby increasing demand for effective treatment options.
• The other cancers segment, which includes adenocarcinomas (e.g., anal sac adenocarcinoma), mammary cancers, brain tumors, nasal tumors, and oral tumors, is projected to grow at the fastest CAGR of 14.05% during the forecast period. This growth is attributed to the rising prevalence of these conditions and growing awareness among pet owners about early detection and treatment.

Order a free sample PDF of the U.S. Veterinary Oncology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 722.86 million
• 2030 Projected Market Size: USD 1.48 billion
• CAGR (2025 - 2030): 12.58%

Key Companies & Market Share Insights

Key players operating in the U.S. veterinary oncology market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Key Players

• Elanco
• Boehringer Ingelheim International GmbH
• Zoetis
• Elekta AB
• PetCure Oncology
• Accuray Incorporated
• Varian Medical Systems, Inc. (parent company: Siemens Healthineers)
• Virbac
• Merck & Co., Inc.
• Dechra Pharmaceuticals PLC
• NovaVive Inc.
• Ardent Animal Health, LLC (A BreakthrU Company)
• Karyopharm Therapeutics, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. veterinary oncology market is poised for strong growth, supported by technological advancements, rising cancer incidence in pets, and increasing demand for early detection and personalized therapies. With dogs accounting for the majority of cancer diagnoses, the canine segment continues to dominate while driving innovation in therapies such as immunotherapy and advanced surgical techniques. The availability of cutting-edge treatments like ECI highlights the industry’s transition toward precision medicine. As awareness among pet owners grows and veterinary research advances, the U.S. market will remain a leader in veterinary oncology, ensuring improved treatment outcomes and better quality of life for companion animals.